Ozempic Trial Shows Drug Turns People Off Alcohol
Results showed that people craved and drank less alcohol when on the drug, according to the findings of a recent study.
Ozempic shows some promise for alcohol use disorder
Novo Nordisk’s blockbuster GLP-1 diabetes drug Ozempic led to improvements in some measures of alcohol use disorder in a small trial, researchers reported on Wednesday.
Ozempic's Potential in Combating Alcohol Use Disorder Uncovered
In a small trial, Novo Nordisk's diabetes drug Ozempic showed promise in reducing alcohol consumption and cravings in individuals with alcohol use disorder. Participants treated with Ozempic displayed a significant reduction in alcohol intake compared to those given a placebo.
More Evidence Ozempic Can Curb Alcoholism
"The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder." His team published its findings Feb. 12 in JAMA Psychiatry.
Ozempic shown to reduce drinking in first trial in alcohol-use disorder
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don’t just curb their desire to eat; for some, they also lead them to drink less alcohol.
Ozempic’s Active Ingredient May Reduce Alcohol Cravings, Study Says
The active ingredient in Ozempic and Wegovy was linked to reduced cravings for drinking alcohol among people with alcohol use disorder, according to a small study published Wednesday in the journal JAMA Psychiatry,
Why Novo Nordisk Stock Keeps Going Down
Novo Nordisk ( NVO -2.98%) stock is in a funk. Shares of the GLP-1 diet drug manufacturer have been sliding all week long, ...
Novo Suffers Loss in Lawsuit Against Pharmacy’s Copycat Ozempic
Novo Nordisk A/S failed to convince a federal judge that a pharmacy in Florida making compounded versions of its diabetes and ...
Some Ozempic users are developing serious eye issues that lead to blindness
A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.
Ozempic and Blindness: What We Know About Weight Loss Side Effects
Symptoms of NAION can include blurred vision, peripheral vision loss, dark spots in vision, and changes in color perception. Though the exact mechanism is not fully understood, researchers hypothesize ...
Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs
The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Philadelphia Tribune1d
Low doses of Ozempic reduced weekly alcohol cravings, study says
Novo Nordisk A/S’s Ozempic helped reduce alcohol cravings in a small study, more evidence that the popular injections may ...
Novo Nordisk Stock Rises as Q4 Wegovy Sales More Than Double
Novo Nordisk's U.S.-listed shares rose 5% in intraday trading after the Ozempic and Wegovy maker's better-than-estimated ...
Novo Nordisk Earnings Boost Stock in Ozempic Maker
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, ...
As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs
Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.